Emerging clinical evidence suggests that Novera Retatrutide, a twin-action therapy from Novo Nordisk, could represent a substantial breakthrough in weight loss. Beyond many existing treatments, Retatrutide affects both the GLP-1 hormone and glucose-dependent insulinotropic polypeptide (GIP), pote… Read More